ABBOTT LABORATORIES — Director's Dealing 2023

Feb 23, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2023-02-17

Reporting Person: Funck, Jr. Robert E. (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-17	Common shares without par value	A	24419	—	Acquired	231001	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-17	Option (right to buy)	$106.24	A	96301	Acquired	2033-02-16	Common Shares (96301)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common shares without par value	10000	Indirect
Common shares without par value	10000	Indirect
Common shares without par value	18405	Indirect
Common shares without par value	500	Indirect

Footnotes

F1: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

F2: Held in daughter's annual gift trust. The reporting person disclaims beneficial ownership of all securities held by the trust.

F3: Balance in the Abbott Laboratories Stock Retirement Trust as of February 17, 2023.

F4: The reporting person disclaims beneficial ownership of all securities held by his daughter.

F5: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 32,100 on February 17, 2024, 32,100 on February 17, 2025, and 32,101 on February 17, 2026.